JP7410017B2 - 新規なテトラゾール化合物および結核の治療におけるそれらの使用 - Google Patents

新規なテトラゾール化合物および結核の治療におけるそれらの使用 Download PDF

Info

Publication number
JP7410017B2
JP7410017B2 JP2020508427A JP2020508427A JP7410017B2 JP 7410017 B2 JP7410017 B2 JP 7410017B2 JP 2020508427 A JP2020508427 A JP 2020508427A JP 2020508427 A JP2020508427 A JP 2020508427A JP 7410017 B2 JP7410017 B2 JP 7410017B2
Authority
JP
Japan
Prior art keywords
tetrazol
benzenesulfonamide
hydroxyethyl
methyl
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020508427A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531425A (ja
JP2020531425A5 (https=
Inventor
カルロス、アレムパルテ-ガジャルド
ルーデス、エンシーナス
ホルヘ、エスキビアス、プロベンシオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of JP2020531425A publication Critical patent/JP2020531425A/ja
Publication of JP2020531425A5 publication Critical patent/JP2020531425A5/ja
Application granted granted Critical
Publication of JP7410017B2 publication Critical patent/JP7410017B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04Five-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/061,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020508427A 2017-08-17 2018-08-16 新規なテトラゾール化合物および結核の治療におけるそれらの使用 Active JP7410017B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382574 2017-08-17
EP17382574.6 2017-08-17
PCT/EP2018/072205 WO2019034729A1 (en) 2017-08-17 2018-08-16 NOVEL TETRAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF TUBERCULOSIS

Publications (3)

Publication Number Publication Date
JP2020531425A JP2020531425A (ja) 2020-11-05
JP2020531425A5 JP2020531425A5 (https=) 2021-09-24
JP7410017B2 true JP7410017B2 (ja) 2024-01-09

Family

ID=59713960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020508427A Active JP7410017B2 (ja) 2017-08-17 2018-08-16 新規なテトラゾール化合物および結核の治療におけるそれらの使用

Country Status (19)

Country Link
US (1) US11072591B2 (https=)
EP (1) EP3668856B1 (https=)
JP (1) JP7410017B2 (https=)
KR (1) KR102661367B1 (https=)
CN (1) CN110997651B (https=)
AU (1) AU2018317812C1 (https=)
CA (1) CA3072854A1 (https=)
CY (1) CY1124577T1 (https=)
DK (1) DK3668856T3 (https=)
ES (1) ES2885573T3 (https=)
HR (1) HRP20211326T1 (https=)
HU (1) HUE055732T2 (https=)
LT (1) LT3668856T (https=)
PL (1) PL3668856T3 (https=)
PT (1) PT3668856T (https=)
RS (1) RS62267B1 (https=)
SI (1) SI3668856T1 (https=)
SM (1) SMT202100515T1 (https=)
WO (1) WO2019034729A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111184718A (zh) * 2018-11-15 2020-05-22 鲁南制药集团股份有限公司 法罗培南在制备治疗初治病原学阳性肺结核药物中的用途
CN115403533B (zh) * 2021-05-28 2023-08-25 永康市第一人民医院 一种1-苯乙烯基-1,2,3-三氮唑化合物及其制备方法和应用
CN116102483B (zh) * 2021-11-09 2025-01-17 中国医学科学院药物研究所 取代吡咯-2,5-二酮类化合物及其制备方法和用途
CN116726018A (zh) * 2023-08-02 2023-09-12 上海市肺科医院(上海市职业病防治院) 一种贝达喹啉、德拉马尼、氯法齐明和吡嗪酰胺的联用和应用
CN117379430A (zh) * 2023-10-11 2024-01-12 深圳市第三人民医院(深圳市肝病研究所) 一种地拉韦啶的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004780A1 (en) 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Therapeutic or prophylactic agent for glomerulopathy
WO2017066964A1 (en) 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120003499A (ko) * 2007-04-05 2012-01-10 지멘스 메디컬 솔루션즈 유에스에이, 인크. 클릭 화학을 이용한 탄산탈수효소―ⅰⅹ에 대한 분자 영상화 프로브의 제조

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004780A1 (en) 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Therapeutic or prophylactic agent for glomerulopathy
WO2017066964A1 (en) 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
EP3668856B1 (en) 2021-06-23
WO2019034729A1 (en) 2019-02-21
BR112020003247A2 (pt) 2020-08-18
JP2020531425A (ja) 2020-11-05
CA3072854A1 (en) 2019-02-21
ES2885573T3 (es) 2021-12-14
CN110997651A (zh) 2020-04-10
SMT202100515T1 (it) 2021-11-12
PL3668856T3 (pl) 2021-12-13
CY1124577T1 (el) 2022-07-22
RU2020110818A (ru) 2021-09-17
EP3668856A1 (en) 2020-06-24
US20200231555A1 (en) 2020-07-23
RS62267B1 (sr) 2021-09-30
US11072591B2 (en) 2021-07-27
KR20200041915A (ko) 2020-04-22
HRP20211326T1 (hr) 2021-11-26
CN110997651B (zh) 2023-01-03
PT3668856T (pt) 2021-09-15
AU2018317812B2 (en) 2021-04-15
DK3668856T3 (da) 2021-09-20
HUE055732T2 (hu) 2021-12-28
RU2020110818A3 (https=) 2021-10-11
AU2018317812A1 (en) 2020-02-20
AU2018317812C1 (en) 2021-08-26
KR102661367B1 (ko) 2024-04-29
SI3668856T1 (sl) 2021-11-30
LT3668856T (lt) 2021-09-27

Similar Documents

Publication Publication Date Title
JP7410017B2 (ja) 新規なテトラゾール化合物および結核の治療におけるそれらの使用
US10221162B2 (en) Triazole agonists of the APJ receptor
EP3191478B1 (en) Compounds and compositions as raf kinase inhibitors
US10245267B2 (en) Biaryl amide compounds as kinase inhibitors
JP6308504B2 (ja) タンパク質キナーゼ阻害薬
WO2011147259A1 (zh) 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
US11427558B1 (en) Indazoles and azaindazoles as LRRK2 inhibitors
EA033758B1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EP2411368A1 (fr) Derives de nicotinamide, leur preparation et leur application en therapeutique comme anticancereux
WO2021064677A1 (en) Inhibitors of human immunodeficiency virus replication
RU2800930C2 (ru) Новые производные тетразола и их применение в лечении туберкулеза
BR112020003247B1 (pt) Compostos de tetrazol, uso dos ditos compostos para o tratamento de infecção micobacteriana ou de doença causada pela mesma, composição farmacêutica e combinação que compreende os compostos
CN121712766A (zh) 吗啉促食欲素受体拮抗剂
HK40039580A (en) Condensed azaheteroaryl compounds having antibacterial activity against tuberculosis bacteria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210816

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231221

R150 Certificate of patent or registration of utility model

Ref document number: 7410017

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150